TY - JOUR
T1 - Operation Warp Speed
T2 - implications for global vaccine security
AU - Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members
AU - Kim, Jerome H.
AU - Hotez, Peter
AU - Batista, Carolina
AU - Ergonul, Onder
AU - Figueroa, J. Peter
AU - Gilbert, Sarah
AU - Gursel, Mayda
AU - Hassanain, Mazen
AU - Kang, Gagandeep
AU - Lall, Bhavna
AU - Larson, Heidi
AU - Naniche, Denise
AU - Sheahan, Timothy
AU - Shoham, Shmuel
AU - Wilder-Smith, Annelies
AU - Strub-Wourgaft, Nathalie
AU - Yadav, Prashant
AU - Bottazzi, Maria Elena
N1 - Funding Information:
The OWS programme is focused on the USA and approval by the US Food and Drug Administration. The USA continues to lead globally in the number of COVID-19 cases, and its deaths due to COVID-19 are approaching 560 000 people in March, 2021. However, the global toll of infection (ie, approaching 121·2 million people) and deaths (ie, nearly 2·7 million) means that vaccines that are developed under OWS should also be considered for global distribution. Interestingly, several of the companies that are supported by OWS also received funding from CEPI, which should require global access. Failing to provide equity in the early distribution of SARS-CoV-2 vaccines, according to modelling by Chinazzi and colleagues, could result in a doubling of global mortality. 5 Leveraging the efforts of OWS for global health and bringing safe and effective vaccine solutions to people around the world in a timely manner is a crucial endeavour and too important to fail. 5,6
Publisher Copyright:
© 2021 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license
PY - 2021/7
Y1 - 2021/7
N2 - Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
AB - Several global efforts are underway to develop COVID-19 vaccines, and interim analyses from phase 3 clinical testing have been announced by nine organisations: Pfizer, the Gamaleya Research Institute of Epidemiology and Microbiology, Moderna, AstraZeneca, Sinopharm Group, Sinovac Biotech, Johnson & Johnson, Novavax, and CanSino Biologics. The US programme known as Operation Warp Speed provided US$18 billion in funding for development of vaccines that were intended for US populations. Depending on safety and efficacy, vaccines can become available through mechanisms for emergency use, expanded access with informed consent, or full licensure. An important question is: how will these Operation Warp Speed vaccines be used for COVID-19 prevention in global health settings? We address some key questions that arise in the transition from US to global vaccine prevention efforts and from ethical and logistical issues to those that are relevant to global vaccine security, justice, equity, and diplomacy.
UR - http://www.scopus.com/inward/record.url?scp=85103942011&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103942011&partnerID=8YFLogxK
U2 - 10.1016/S2214-109X(21)00140-6
DO - 10.1016/S2214-109X(21)00140-6
M3 - Review article
C2 - 33780663
AN - SCOPUS:85103942011
SN - 2214-109X
VL - 9
SP - e1017-e1021
JO - The Lancet Global Health
JF - The Lancet Global Health
IS - 7
ER -